Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausal women

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 10, 1999, Pages 534-547

  Cohen, Louis ^a   Coxwell, Wayne L ^k   Melchione, Thomas ^b   Koltun, William ^c   Gibson, Eric ^d   Gupta, Niroo ^d   Roberts, Maria ^d   Baldwin, Davis W ^k   Berga, Sarah L ^e   MacIlwain, Harris ^f   Reisman, Howard A ^g   Richards, Joanne ^h   Rosenstein, Morton G ^k   Stoltz, Randall R ⁱ   Teutsh, Carol Beth ^j  

^a Clinical Studies Ltd   (United States)

^b Pacific Clinical Coordinators   (United States)

^c Medical Center for Clinical Research   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Tampa Medical Group   (United States)

^g Atlanta North Gynecology   (United States)

^h McCarty/Hernon Associates Inc   (United States)

ⁱ GFI Pharmaceutical Services Inc   (United States)

^j Northside Intern/Endocrinologists   (United States)

^k NONE

more..

Author keywords

Estradiol; Hormone replacement therapy; Postmenopausal; Vasomotor symptoms

Indexed keywords

ESTRADIOL; ESTROGEN;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EDEMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FLATULENCE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LEUKORRHEA; MAJOR CLINICAL STUDY; MASTALGIA; MIGRAINE; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; URTICARIA;

EID: 0033393662     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(99)80062-9     Document Type: Article

References (17)

1. Matthews KA. Myths and realities of the menopause. Psychosom Med. 1992;54:1-9.
2. Matthews KA, Wing RR, Kuller LH, et al. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med. 1994;154:2349-2355.
3. Matthews KA, Wing RR, Kuller LH, et al. Influences of natural menopause on psychological characteristics and symptoms of middle-aged healthy women. J Consult Clin Psychol. 1990;58:345-351.
4. Kuh DL, Wadsworth M, Hardy R. Women's health in midlife: The influence of the menopause, social factors and health in earlier life. Br J Obstet Gynaecol. 1997;104:923-933.
5. Khan SA, Pace JE, Cox ML, et al. Climacteric symptoms in healthy middle-aged women. Br J Clin Pract. 1994;48:240-242.
6. Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. Br J Obstet Gynaecol. 1997;104(Suppl 16):4-13.
7. Balfour JA, McTavish D. Transdermal estradiol: A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis. Drugs Aging. 1992;2:487-507.
8. Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estradiol therapy. Drug Saf. 1993;9:365-379.
9. Stevenson JC, Crook D, Godsland IF, et al. Oral versus transdermal hormone replacement therapy. Int J Fertil. 1993;38(Suppl 1):30-35.
10. Good WR, John VA, Ramirez M, Higgins JE. Double-masked, multicenter study of estradiol matrix transdermal delivery system (Alora™) versus placebo in postmenopausal women experiencing menopausal symptoms. Clin Ther. 1996;18:1093-1105.
11. Whitehead MI, Padwick ML, Endacott J, Pryse-Davis J. Endometrial responses to transdermal estradiol in postmenopausal women. Am J Obstet Gynecol. 1985;152:1079-1084.
12. Clisham PR, Cedars MI, Greendale G, et al. Long-term transdermal estradiol therapy: Effects on endometrial histology and bleeding patterns. Obstet Gynecol. 1992;79:196-201.
13. Rozenberg S, Ylikorkala O, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: Vasomotor symptoms, bleeding patterns, and serum lipids. Int J Fertil Women's Med. 1997;42(Suppl 2):376-387.
14. Han RG. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors. Am J Obstet Gynecol. 1989;161:1854-1858.
15. Harris ST, Genant HK, Baylink DJ, et al. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch Intern Med. 1991;151:1980-1984.
16. Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol. 1992;166:479-488.
17. Whitehead MI, Fraser D. The effects of estrogens and progestogens on the endometrium: Modern approach to treatment. Obstet Gynecol Clin North Am. 1987;14:299-320.